Difference of serum tumor markers in different clinical stages of elderly patients with non-small cell lung cancer and evaluation of diagnostic value.

IF 2 4区医学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Journal of Medical Biochemistry Pub Date : 2023-10-27 DOI:10.5937/jomb0-39798

Wen Wen Qin, Ping Wang, CuiMin Ding, Fei Peng

{"title":"Difference of serum tumor markers in different clinical stages of elderly patients with non-small cell lung cancer and evaluation of diagnostic value.","authors":"Wen Wen Qin, Ping Wang, CuiMin Ding, Fei Peng","doi":"10.5937/jomb0-39798","DOIUrl":null,"url":null,"abstract":"Background: To explore the difference and diagnostic value evaluation of serum tumor markers in different clinical stages of elderly non-small cell lung cancer (NSCLC) patients.Methods: Select 100 elderly NSCLC patients admitted to our hospital from June 2018 to June 2021, collect the general data, pathology data and imaging data of the patients, and the patients were divided into I-IV clinical stages according to the International Union Against Cancer (UICC) 8th edition lung cancer TNM staging standard. Detect the subjects' peripheral serum tumor markers, serum carcinoembryonic antigen (CEA), cytokeratin fragment 21-1 (CYFRA21-1), squamous cell carcinoma-associated antigen (SCCA), carbohydrate antigen 125 (CA125) and sugar Class antigen 199 (CA199). Compare the differences of serum CEA, CYFRA21-1, SCCA, CA125, CA199 levels in different clinical stages of elderly NSCLC patients, and the diagnostic value of the above indicators for elderly NSCLC patients was analyzed by receiver operating characteristic curve (ROC curve) and area under the curve (AUC).","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10710819/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5937/jomb0-39798","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: To explore the difference and diagnostic value evaluation of serum tumor markers in different clinical stages of elderly non-small cell lung cancer (NSCLC) patients.

Methods: Select 100 elderly NSCLC patients admitted to our hospital from June 2018 to June 2021, collect the general data, pathology data and imaging data of the patients, and the patients were divided into I-IV clinical stages according to the International Union Against Cancer (UICC) 8th edition lung cancer TNM staging standard. Detect the subjects' peripheral serum tumor markers, serum carcinoembryonic antigen (CEA), cytokeratin fragment 21-1 (CYFRA21-1), squamous cell carcinoma-associated antigen (SCCA), carbohydrate antigen 125 (CA125) and sugar Class antigen 199 (CA199). Compare the differences of serum CEA, CYFRA21-1, SCCA, CA125, CA199 levels in different clinical stages of elderly NSCLC patients, and the diagnostic value of the above indicators for elderly NSCLC patients was analyzed by receiver operating characteristic curve (ROC curve) and area under the curve (AUC).

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

非小细胞肺癌老年患者不同临床阶段血清肿瘤标志物的差异及诊断价值评估

背景：探讨血清肿瘤标志物在老年非小细胞肺癌（NSCLC）患者不同临床阶段的差异及诊断价值评估：探讨血清肿瘤标志物在不同临床分期老年非小细胞肺癌（NSCLC）患者中的差异及诊断价值评价：选择2018年6月-2021年6月我院收治的100例老年NSCLC患者，收集患者的一般资料、病理资料及影像学资料，根据国际抗癌联盟（UICC）第8版肺癌TNM分期标准将患者分为I-IV期临床分期。检测受试者外周血肿瘤标志物、血清癌胚抗原（CEA）、细胞角蛋白片段21-1（CYFRA21-1）、鳞状细胞癌相关抗原（SCCA）、碳水化合物抗原125（CA125）和糖类抗原199（CA199）。比较不同临床分期老年 NSCLC 患者血清 CEA、CYFRA21-1、SCCA、CA125、CA199 水平的差异，并通过接收者操作特征曲线（ROC 曲线）和曲线下面积（AUC）分析上述指标对老年 NSCLC 患者的诊断价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Medical Biochemistry BIOCHEMISTRY & MOLECULAR BIOLOGY-

CiteScore

3.00

自引率

12.00%

发文量

审稿时长

>12 weeks

期刊介绍： The JOURNAL OF MEDICAL BIOCHEMISTRY (J MED BIOCHEM) is the official journal of the Society of Medical Biochemists of Serbia with international peer-review. Papers are independently reviewed by at least two reviewers selected by the Editors as Blind Peer Reviews. The Journal of Medical Biochemistry is published quarterly. The Journal publishes original scientific and specialized articles on all aspects of clinical and medical biochemistry, molecular medicine, clinical hematology and coagulation, clinical immunology and autoimmunity, clinical microbiology, virology, clinical genomics and molecular biology, genetic epidemiology, drug measurement, evaluation of diagnostic markers, new reagents and laboratory equipment, reference materials and methods, reference values, laboratory organization, automation, quality control, clinical metrology, all related scientific disciplines where chemistry, biochemistry, molecular biology and immunochemistry deal with the study of normal and pathologic processes in human beings.